Opyl is claiming credit for predicting a positive interim outcome of the $DXB/Dimerix ACTION3 Phase 3 trial of DMX-200 in FSGS Kidney Disease.
Bernice Averion, Medtech Marketing Marketing Manager of OPL's TrialKey business:
"...Opyl foresaw this success, predicting a high probability of 74.51% even before the official results were revealed.
"As a result, DXB's share price has experienced a notable surge, underlining the potential benefits of predictive tools like TrialKey for investors.
"Imagine having the foresight to spot viable investments before the market catches on!"
Opyl is claiming credit for predicting a positive interim...
Add OPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.218M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 798533 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 184163 | 2 |
View Market Depth
| Last trade - 11.35am 02/05/2024 (20 minute delay) ? |
| OPL (ASX) Chart |
Day chart unavailable